SUO 2018: Update on the SEMS Trial - Surgery in Early Metastatic Seminoma

Phoenix, Arizona (UroToday.com) Dr. Daneshmand wrapped up the testicular cancer session with an update on the SEMS trial. The current standard of care for node-positive seminoma patients is either radiation or chemotherapy. There has been no change in recommendation for decades. However, as seen by Dr. Travis’ work, these treatments are associated with long-term morbidity, such as 2nd malignancy, cardiovascular toxicity, metabolic syndrome, and pulmonary toxicity. Especially as the cure rates are so high, patients have a long time to develop these toxicities.

Current NCCN management of Stage IIA seminoma (low-volume metastatic disease) is:

Figure 1

RPLND has known efficacy in treating germ cell tumors – in the primary setting for NSGCT (stage 1 and 2) and in the post-chemotherapy setting for seminoma and NSGCT. Based on this, Dr. Daneshmand and Dr. Brian Hu (Loma Linda) hypothesized that it could be useful in low-volume seminoma patients as well.

In their pilot study of 4 patients, they found that patients did well – LOS was 3 days, one Clavien 1 complication, all maintained antegrade ejaculation, and no adjuvant therapy was required through 2 years. In updated follow-up, all four patients have not required additional therapy through 5 years.

This in combination with other small series seemed to support the low recurrence rates following primary RPLND – much better than radiation or chemotherapy, as seen below:

Figure 2

This was the inception of the SEMS trials – with Drs. Daneshmand and Hu as co-primary investigators.

Inclusion criteria:
Pure seminoma
Stage 1 with 1-3 cm relapse OR presenting with stage IIA/B disease (no more than 2 lymph nodes, 1-3 cm in any direction)
LN must be in RPLND template
Imaging within 6 weeks of surgery
Normal serum tumor markers (1.5 ULN)
Relapse within 3 years of orchiectomy (to exclude late-relapse disease)

Outcomes planned are as follows:

Figure 3
Of note, similar to the SWOG studies, intra-operative photographs must be submitted to establish degree of node dissection.
Surgeon’s must meet volume requirements (8 RPLNDs/year or 24 in 3 years)
All are done open to remove one more variable

Planned accrual was for 55 patients over 4 years; 15 sites have been activated.
To date, 44 patients have been accrued.

Safety interim analysis has been met! Mostly Clavien 1-2 adverse events – 2 patients with Clavien 3: 1 PE and 1 chylous ascites.

The study is ongoing and they are almost done accruing patients. It will take 2 years for final results, but this may be a paradigm changing clinical trial! We look forward to the results.

Presented By: Siamak Daneshmand, MD

Written by: Thenappan Chandrasekar, MD, Clinical Instructor, Thomas Jefferson University, @tchandra_uromd, @TjuUrology, at the 19th Annual Meeting of the Society of Urologic Oncology (SUO), November 28-30, 2018 – Phoenix, Arizona
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe